References
- Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022 Jan;55(1):31–55.
- Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;4:851–63.
- Brennan E, Kantharidis P, Cooper ME, Godson C. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol. 2021 Nov;17(11):725–39.
- Neuhofer A, Zeyda M, Mascher D, Itariu BK, Murano I, Leitner L, et al. Impaired Local Production of Proresolving Lipid Mediators in Obesity and 17-HDHA as a Potential Treatment for Obesity-Associated Inflammation. Diabetes. 2013 Jun 1;62(6):1945–56.
- Liu X, Tang Y, Luo Y, Gao Y, He L. Role and mechanism of specialized pro-resolving mediators in obesity-associated insulin resistance. Lipids Health Dis. 2024 Jul 30;23(1):234.
- Dludla PV, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, et al. Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. World J Diabetes. 2023 Mar 15;14(3):130–46.
- De Gaetano M, McEvoy C, Andrews D, Cacace A, Hunter J, Brennan E, et al. Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. Front Pharmacol. 2018 Dec 19;9:1488.
- Brennan EP, Mohan M, McClelland A, Tikellis C, Ziemann M, Kaspi A, et al. Lipoxins Regulate the Early Growth Response–1 Network and Reverse Diabetic Kidney Disease. J Am Soc Nephrol. 2018 May;29(5):1437–48.
- Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Front Immunol [Internet]. 2016 Apr 26 [cited 2024 Jul 4];7. Available from: http://journal.frontiersin.org/Article/10.3389/fimmu.2016.00160/abstract
- Schmid T, Brüne B. Prostanoids and Resolution of Inflammation – Beyond the Lipid-Mediator Class Switch. Front Immunol. 2021 Jul 12;12:714042.
- Buckley CD, Gilroy DW, Serhan CN. Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. Immunity. 2014 Mar;40(3):315–27.
- Conte MS, Desai TA, Wu B, Schaller M, Werlin E. Pro-resolving lipid mediators in vascular disease. J Clin Invest. 2018 Aug 31;128(9):3727–35.
- Pan G, Zhang P, Yang J, Wu Y. The regulatory effect of specialized pro-resolving mediators on immune cells. Biomed Pharmacother. 2022 Dec;156:113980.
- Rangarajan S, Orujyan D, Rangchaikul P, Radwan MM. Critical Role of Inflammation and Specialized Pro-Resolving Mediators in the Pathogenesis of Atherosclerosis. Biomedicines. 2022 Nov 6;10(11):2829.
- Kourtzelis I, Mitroulis I, Von Renesse J, Hajishengallis G, Chavakis T. From leukocyte recruitment to resolution of inflammation: the cardinal role of integrins. J Leukoc Biol. 2017 Mar 14;102(3):677–83.
- Romano M. Lipoxin and Aspirin-Triggered Lipoxins. Sci World J. 2010;10:1048–64.
- Vartak T, Godson C, Brennan E. Therapeutic potential of pro-resolving mediators in diabetic kidney disease. Adv Drug Deliv Rev. 2021 Nov;178:113965.
- Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med. 2013 May;5(5):661–74.
- Tang S, Wan M, Huang W, Stanton RC, Xu Y. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases. Mediators Inflamm. 2018;2018:1–8.
- Kwon Y. Immuno-Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega-3 Fatty Acids in Metabolic Syndrome. Mol Nutr Food Res. 2020 Feb;64(4):1900824.
- López-Vicario C, Titos E, Walker ME, Alcaraz-Quiles J, Casulleras M, Durán-Güell M, et al. Leukocytes from obese individuals exhibit an impaired SPM signature. FASEB J. 2019 Jun;33(6):7072–83.
- Titos E, Rius B, López-Vicario C, Alcaraz-Quiles J, García-Alonso V, Lopategi A, et al. Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. J Immunol. 2016 Oct 15;197(8):3360–70.
- Börgeson E, Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol [Internet]. 2012 [cited 2024 Jul 13];3. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2012.00318/abstract
- Andrews D, Godson C. Lipoxins and synthetic lipoxin mimetics: Therapeutic potential in renal diseases. Biochim Biophys Acta BBA - Mol Cell Biol Lipids. 2021 Aug;1866(8):158940.
- Bai Y, Wang J, He Z, Yang M, Li L, Jiang H. Mesenchymal Stem Cells Reverse Diabetic Nephropathy Disease via Lipoxin A4 by Targeting Transforming Growth Factor β (TGF-β)/smad Pathway and Pro-Inflammatory Cytokines. Med Sci Monit. 2019 Apr 26;25:3069–76.
- Goicoechea M, Sanchez-Niño MD, Ortiz A, García De Vinuesa S, Quiroga B, Bernis C, et al. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukot Essent Fatty Acids. 2017 Oct;125:8–13.
- Brennan EP, Mohan M, McClelland A, De Gaetano M, Tikellis C, Marai M, et al. Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis. Diabetes. 2018 Dec 1;67(12):2657–67.
- Fredman G, Spite M. Specialized pro-resolving mediators in cardiovascular diseases. Mol Aspects Med. 2017 Dec;58:65–71.
- Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AHK, Pande R, et al. Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. Am J Pathol. 2010 Oct;177(4):2116–23.
- Petri MH, Laguna-Fernandez A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, et al. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E −/− mice. Br J Pharmacol. 2017 Nov;174(22):4043–54.
- Souza PR, Marques RM, Gomez EA, Colas RA, De Matteis R, Zak A, et al. Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study. Circ Res. 2020 Jan 3;126(1):75–90.
- Schaller MS, Chen M, Colas RA, Sorrentino TA, Lazar AA, Grenon SM, et al. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease. J Am Heart Assoc. 2020 Aug 4;9(15):e016113.
- Mas E, Barden A, Burke V, Beilin LJ, Watts GF, Huang RC, et al. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin Nutr. 2016 Apr;35(2):331–6.
- Al-Shaer AE, Regan J, Buddenbaum N, Tharwani S, Drawdy C, Behee M, et al. Enriched Marine Oil Supplement Increases Specific Plasma Specialized Pro-Resolving Mediators in Adults with Obesity. J Nutr. 2022 Jul;152(7):1783–91.